Market closedNon-fractional
ImmunityBio/IBRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ImmunityBio
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
Ticker
IBRX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
628
Website
immunitybio.com
ImmunityBio Metrics
BasicAdvanced
$3.8B
Market cap
-
P/E ratio
-$1.05
EPS
-0.31
Beta
-
Dividend rate
Price and volume
Market cap
$3.8B
Beta
-0.31
Financial strength
Current ratio
3.641
Quick ratio
3.211
Long term debt to equity
-128.614
Total debt to equity
-129.587
Interest coverage (TTM)
-2.52%
Management effectiveness
Return on assets (TTM)
-57.95%
Return on equity (TTM)
98.37%
Valuation
Price to revenue (TTM)
10,358.491
Price to book
-5.37
Price to tangible book (TTM)
-5.24
Price to free cash flow (TTM)
-7.576
Growth
Revenue change (TTM)
-48.46%
Earnings per share change (TTM)
-0.05%
3-year revenue growth (CAGR)
-19.50%
3-year earnings per share growth (CAGR)
14.65%
What the Analysts think about ImmunityBio
Analyst Ratings
Majority rating from 2 analysts.
ImmunityBio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$134M
-42.52%
Profit margin
0.00%
-100.00%
ImmunityBio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.32
-$0.19
-$0.35
-$0.20
-
Expected
-$0.24
-$0.26
-$0.18
-$0.16
-$0.17
Surprise
36.17%
-25.49%
94.44%
25.00%
-
ImmunityBio News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ImmunityBio stock?
ImmunityBio (IBRX) has a market cap of $3.8B as of July 27, 2024.
What is the P/E ratio for ImmunityBio stock?
The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of July 27, 2024.
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of -0.31. This means that it has an inverse relation to market volatility.
Buy or sell ImmunityBio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.